• 1
    Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mullerian tumours treated with platinum-based chemotherapy. Obstet Gynecol. 1995: 85: 735739.
  • 2
    Gourley C, Al-Nafussi A, Abdulkader M, Smyth J, Gabra H. Malignant mixed mesodermal tumours: biology and clinical aspects. Eur J Cancer 2002; 38: 14371446.
  • 3
    Hanjani P, Peterson RO, Lipton SE, Nolte SA. Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: report of eight cases and review of literature. Obstet Gynecol Surv. 1983: 38: 345537.
  • 4
    Clarke TJ. Histogenesis of ovarian malignant mixed mesodermal tumours. J Clin Pathol. 1990: 43: 287290.
  • 5
    Masuda A, Takeda A, Fukami H, Yamada C, Matsuyama M. Characteristics of cell lines established from a mixed mesodermal tumor of the ovary. Carcinomatous cells are changeable to carcinoma cells. Cancer. 1987; 60: 26962703.
  • 6
    de Brito PA, Silverberg SG, Orenstein JM. Carcinomsarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol. 1993; 24: 132142.
  • 7
    Geisinger KR, Dabbas DJ, Marshall RB. Malignant mixed mullerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations. Cancer. 1987; 59: 17811790.
  • 8
    Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990; 9: 119.
  • 9
    Guarino M, Giordano F, Pallotti F, Polizzotti G, Tricomi P, Cristofori E. Malignant mixed mullerian tumor of the uterus. Features favouring its origin from a common cell clone and an epithelial-to-mesenchymal transformation mechanism of histogenesis. Tumori. 1998: 84: 391397.
  • 10
    Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol. 1998; 29: 8287.
  • 11
    Abeln EC, Smit VT, Wessels JW, de Leeuw WJ, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol. 1997; 183: 424431.
  • 12
    Costa MJ, Walls J. Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer. 1996; 77: 533542.
  • 13
    Mayall F, Rutty K, Campbell F, Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology. 1994; 24: 211214.
  • 14
    George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed mullerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol. 1991; 22: 215223.
  • 15
    Harris M, Delap L, Sengupta P, et al. Carcinosarcoma of the ovary. Br J Cancer. 2003; 88: 654657.
  • 16
    Prendeville J, Murphy D, Rennison J, Buckley H, Crowther D. Carcinosarcoma of the ovary treated over a 10-year period at the Christie hospital. Int J Gynecol Cancer. 1994; 4: 200205.
  • 17
    Chang J, Sharpe JC, A'Hern RP, et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol. 1995: 6: 775758.
  • 18
    World Health Organization. Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 19
    Rustin G, Nelstrop A, Bentzen S, Bond S, McLean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in Phase II trials. J Clin Oncol. 2000: 18: 17331739.
  • 20
    Rustin G, Nelstrop A, McLean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 14: 15451551.